NASDAQ:MTEMMolecular Templates Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Molecular Templates Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.02 +0.03 (+0.25 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$11.53Now: $12.02▼$12.1350-Day Range$10.97MA: $12.61▼$15.7652-Week Range$4.51Now: $12.02▼$19.12Volume285,300 shsAverage Volume350,619 shsMarket Capitalization$600.03 millionP/E RatioN/ADividend YieldN/ABeta2.3 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMolecular Templates has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Molecular Templates has a potential upside of 74.7% from its current price of $12.02.Amount of Analyst CoverageMolecular Templates has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesMolecular Templates has received 325 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMolecular Templates has received 298 “underperform” votes. (Add your “underperform” vote.)Community SentimentMolecular Templates has received 52.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote “Outperform” if you believe MTEM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMolecular Templates does not currently pay a dividend.Dividend GrowthMolecular Templates does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Molecular Templates insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,953,000.00 in company stock.Percentage Held by Insiders38.20% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.72% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Molecular Templates are expected to decrease in the coming year, from ($1.66) to ($1.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Templates is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Templates is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Templates has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.62 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MTEM Previous Symbol CUSIP88580720 CIK1183765 Webwww.mtem.com Phone512-869-1555Debt Debt-to-Equity Ratio0.17 Current Ratio2.83 Quick Ratio2.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.27 million Price / Sales26.94 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book4.31Profitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-69,420,000.00 Net Margins-514.48% Return on Equity-105.07% Return on Assets-58.85%Miscellaneous Employees68 Outstanding Shares49,919,000Market Cap$600.03 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $12.02 +0.03 (+0.25 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MTEM News and Ratings via Email Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter. Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions How has Molecular Templates' stock price been impacted by COVID-19? Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MTEM stock has decreased by 9.1% and is now trading at $12.02. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Molecular Templates? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Molecular Templates. When is Molecular Templates' next earnings date? Molecular Templates is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Molecular Templates. How were Molecular Templates' earnings last quarter? Molecular Templates Inc (NASDAQ:MTEM) issued its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.28. The biotechnology company earned $6.91 million during the quarter, compared to the consensus estimate of $5.04 million. Molecular Templates had a negative net margin of 514.48% and a negative return on equity of 105.07%. View Molecular Templates' earnings history. When did Molecular Templates' stock split? How did Molecular Templates' stock split work? Molecular Templates's stock reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split. What price target have analysts set for MTEM? 4 brokers have issued 12 month price targets for Molecular Templates' shares. Their forecasts range from $19.00 to $22.00. On average, they expect Molecular Templates' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 74.7% from the stock's current price. View analysts' price targets for Molecular Templates. Has Molecular Templates been receiving favorable news coverage? News coverage about MTEM stock has trended positive on Friday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Molecular Templates earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news about Molecular Templates. Are investors shorting Molecular Templates? Molecular Templates saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,600,000 shares, an increase of 40.4% from the June 15th total of 1,140,000 shares. Based on an average trading volume of 353,200 shares, the short-interest ratio is currently 4.5 days. Currently, 5.3% of the company's shares are sold short. View Molecular Templates' Short Interest. Who are some of Molecular Templates' key competitors? Some companies that are related to Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Molecular Templates own? Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), CEL-SCI (CVM), Soleno Therapeutics (SLNO), SLS International (SLS) and Amarin (AMRN). Who are Molecular Templates' key executives? Molecular Templates' management team includes the following people: Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)Ms. Jason S Kim, Pres & COO (Age 44)Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39) What is Molecular Templates' stock symbol? Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM." Who are Molecular Templates' major shareholders? Molecular Templates' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bellevue Group AG (6.97%), Federated Hermes Inc. (0.23%), FMR LLC (0.22%), Bank of New York Mellon Corp (0.22%), Monashee Investment Management LLC (0.20%) and Public Employees Retirement Association of Colorado (0.15%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Kevin M Lalande, Longitude Capital Partners Iii and Scott D Morenstein. View institutional ownership trends for Molecular Templates. Which major investors are selling Molecular Templates stock? MTEM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Monashee Investment Management LLC, EAM Investors LLC, Russell Investments Group Ltd., Hancock Whitney Corp, Dupont Capital Management Corp, Strs Ohio, and ClariVest Asset Management LLC. View insider buying and selling activity for Molecular Templates. Which major investors are buying Molecular Templates stock? MTEM stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Public Employees Retirement Association of Colorado, Alps Advisors Inc., Federated Hermes Inc., Algert Global LLC, Swiss National Bank, Athanor Capital LP, and Bank of New York Mellon Corp. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii, and Scott D Morenstein. View insider buying and selling activity for Molecular Templates. How do I buy shares of Molecular Templates? Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Molecular Templates' stock price today? One share of MTEM stock can currently be purchased for approximately $12.02. How big of a company is Molecular Templates? Molecular Templates has a market capitalization of $600.03 million and generates $22.27 million in revenue each year. The biotechnology company earns $-69,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Molecular Templates employs 68 workers across the globe. What is Molecular Templates' official website? The official website for Molecular Templates is www.mtem.com. How can I contact Molecular Templates? Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
